SIGA Technologies (Nasdaq: SIGA) is a commercial-stage company focusing on health security. Its lead program is oral TPOXX (tecovirimat), which was approved by the FDA in 2018 for the treatment of smallpox and is active against all orthopoxviruses.
In this video, SIGA chief scientific officer Dennis Hruby discusses SIGA’s work with additional orthopoxviruses, including Monkeypox. Although SIGA’s TPOXX treatment is not yet approved for Monkeypox, the company continues to make progress and recently entered into a collaboration with Oxford University in the United Kingdom to provide TPOXX under an expanded access protocol to treat individuals affected by Monkeypox in the Central African Republic (CAR). Dennis discusses the company’s progress with these diseases and what we can expect to see next from SIGA.